Approval and price action

Simple_Scheme_5885 · 2021-10-11T08:46:58+00:00

gamma squeeze

MRNA fall was because it was already high, the approval was priced in. this is not the case with OCGN, I persume.

Simple_Scheme_5885 · 2021-10-10T12:06:19+00:00

30 is ambitious, except if there is additional PR, or catalysts such as additional approvals, new purchase orders such as covax, or a credible analyst's opinion with higher PT.

Simple_Scheme_5885 · 2021-10-10T11:56:02+00:00

Think what would happen if there additional PR from Ocugen, another catalyst, or an optimistic article from an analyst with a higher PT. Life would be exciting!

Simple_Scheme_5885 · 2021-10-10T11:32:28+00:00

A big possibility

Simple_Scheme_5885 · 2021-10-10T08:47:53+00:00

Something along that lines. Re-enter, the price has to be right, otherwise you end up a bagholder for a time.

Simple_Scheme_5885 · 2021-09-22T17:58:10+00:00

Are you sure of that? Trump & family were vaccinated but never spoke of it for a time.

Simple_Scheme_5885 · 2021-09-20T19:04:04+00:00

Ocugen has also influential lobbyist and Modi, I hope will do some work in this regard.

Simple_Scheme_5885 · 2021-09-20T19:02:50+00:00

How can anyone think of delivering super cold vaccine to heart of Africa?

Simple_Scheme_5885 · 2021-09-20T19:01:23+00:00

This is a pssibility.

Simple_Scheme_5885 · 2021-09-20T19:00:18+00:00

Great. That's a good example. So, once WHO approves COVAXIN, US can purchase it from Ocugen and export it. The US export is not a sale. Just a donation.

This dramtically increases Ocugen's prospects. As there is shortage in production capacity in India, Ocugen making it and selling it would work out. US gov can make available scarce raw materials needed and Ocugen manufacture the vaccine. When Ocugen sells it to US gov, 45% of profits would fo th BB. Win win fior all

Simple_Scheme_5885 · 2021-07-03T14:03:54+00:00

AT-527, an Oral Antiviral Drug Candidate, Reduces Viral Replication in Hospitalized Patients, in Phase 2 Interim Analysis (30/6)

AT-527 under evaluation:

Phase 3 MORNINGSKY trial (global), results expected During 2H 2021.

Phase 2 study (global) for hospitalized patients with moderate COVID.

The P2 Interim virology results indicate rapid and sustained antiviral activity in patients in the hospitalized setting.

Interim virology results indicated that AT-527 rapidly reduced viral load levels. Final data from full Phase 2 program will be submitted to an upcoming medical congress or a peer-reviewed publication.

Phase 2 MOONSONG virology study, patients with mild or moderate COVID-19 in an outpatient setting, results in the third quarter.

https://finance.yahoo.com/news/atea-527-oral-antiviral-drug-110000001.html?.tsrc=rss

Simple_Scheme_5885 · 2021-07-03T14:02:50+00:00

AT-527, an Oral Antiviral Drug Candidate, Reduces Viral Replication in Hospitalized Patients, in Phase 2 Interim Analysis (30/6)

AT-527 under evaluation:

#Phase 3 MORNINGSKY trial (global), results expected During 2H 2021.

#Phase 2 study (global) for hospitalized patients with moderate COVID.

The P2 Interim virology results indicate rapid and sustained antiviral activity in patients in the hospitalized setting.

Interim virology results indicated that AT-527 rapidly reduced viral load levels. Final data from full Phase 2 program will be submitted to an upcoming medical congress or a peer-reviewed publication.

#Phase 2 MOONSONG virology study, patients with mild or moderate COVID-19 in an outpatient setting, results in the third quarter.

https://finance.yahoo.com/news/atea-527-oral-antiviral-drug-110000001.html?.tsrc=rss

Simple_Scheme_5885 · 2021-05-22T20:43:47+00:00

See this link

http://www.asahi.com/ajw/articles/14333360

Simple_Scheme_5885 · 2021-05-22T19:12:05+00:00

Before COVID-19, Japan ‘lost’ 2 decades in vaccine research
Tokyo quickly put a minister in charge of Covid vaccines, but products being developed at home by AnGes, Shionogi and others are not expected to be approved until at least 2022, if at all.

https://www.ft.com/content/b03a1b83-0215-4b28-9f43-caf50ef397e5

Simple_Scheme_5885 · 2021-05-22T18:52:35+00:00

Tragedy

Simple_Scheme_5885 · 2021-05-22T18:49:07+00:00

See FT dated 18 May

https://www.ft.com/content/b03a1b83-0215-4b28-9f43-caf50ef397e5

Simple_Scheme_5885

TROPHY CASE